Cbl-b-IN-9

• UNSPSC Description:

  Cbl-b-IN-9 (Compound 300) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 5.6 nM and 4.7 nM, respectively[1].

• Target Antigen:

  E1/E2/E3 Enzyme

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cbl-b-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=C(CN1C3=CC(C4(CC5=NN=CN5C)COC4)=CC(C6CC6)=N3)C(C(F)(F)F)=CC(CNC7(CCC7)C)=C2

• Molecular Weight:

  566.62

• References & Citations:

  [1]Jun Liang, et al. Lactams as cbl-b inhibitors. Patent WO2022169997A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2815223-41-5